Navigation Links
Micell Technologies Presents Data on Novel Drug-Eluting Stents

RALEIGH, N.C., April 18, 2007 /PRNewswire/ -- Micell Technologies announced today that the Company will be presenting data on use of its supercritical fluid (SCF) surface modification technology for drug-eluting stents at the upcoming Society for Biomaterials 2007 Annual Meeting, April 19-21 2007 in Chicago, Illinois.

The abstracts describe use of Micell and PNNL's, 2006 R&D 100 Award winning e-RESS technology to create drug-eluting stents containing crystalline drugs, such as sirolimus, and multiple drug combinations such as paclitaxel and heparin.

e-RESS (e for electrostatic, RESS for Rapid Expansion from Supercritical Solution) is a new technology for creating novel drug-eluting materials for cardiovascular stents and other medical devices. The technology was jointly developed by Micell and scientists at Pacific Northwest National Laboratory (PNNL), and has been licensed exclusively to Micell.

This unique technology has the potential to provide improvements to conventional solvent based systems by maintaining control of drug morphology, targeting drug placement within the coating and customizing elution rates of single or multiple drugs. In addition, the SCF method avoids solvents and high temperatures so it can be used with new therapeutic classes, such as proteins or genes, in addition to existing therapeutic agents.

Link to abstract 1: (http://www.micell.com/development1.pdf)

Link to abstract 2: (http://www.micell.com/development2.pdf)

While drug-eluting stents have demonstrated dramatic improvements in early restenosis rates compared to bare metal stents, concerns over late stent thrombosis have been the subject of much recent discussion in the medical community and the media. These concerns have been driven largely by a number of issues including inherently thrombogenic polymers, residual drugs and patient compliance issues related to the necessary oral anti-platelet therapy such as Plavix and aspirin, required of patients who receive drug-eluting stents.

"Our technology provides an opportunity for optimal design of therapeutic profiles using both anti-restenosis and anti-thrombotic compounds to address both short and long-term safety of drug-eluting stents," said James B. McClain, founder and Chief Technology Officer of Micell Technologies. "This approach which includes multi-drug formulations in biodegradable polymers has the potential to provide improved benefits for both patients and clinicians."

Micell Technologies' novel approach to surface modification of medical devices provides an opportunity to deliver the next generation of drug-eluting stents by maintaining morphology of therapeutic compounds and providing manufacturing processes that apply discrete and independent therapies within a single, multi-therapy coating.

About Micell

Micell Technologies is a privately-held, early-stage biomedical company dedicated to applying its unique surface and polymer modification technologies for improved patient benefits and accelerated product development for medical device and drug delivery applications. The Company's patented processes and methods for medical device surface modification using supercritical fluids are focused on improvements to current polymer based drug-eluting technologies. To learn more, please visit our website at www.micell.com

Contact: James McClain Ph.D., Chief Technology Officer

Micell Technologies: (919) 313-2111

CONTACT: James McClain Ph.D., Chief Technology Officer of MicellTechnologies, +1-919-313-2111

Web site: http://www.micell.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Neose Technologies to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. New Report Looking at Chiral Technologies Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals
3. Palatin Technologies and King Pharmaceuticals Report Data Showing Improvements in Sexual Relationship and Self-Esteem in Patients with Erectile Dysfunction Treated with Bremelanotide
4. Palatin Technologies and King Pharmaceuticals Announce Plan To Present Results of Bremelanotide Phase 2b Studies in Men With Erectile Dysfunction
5. Genelabs Technologies Announces Presentation of Data on Non-Nucleoside HCV Polymerase Inhibitor at 20th International Conference on Antiviral Research Meeting
6. OncoGenex Technologies Announces Phase II Data of OGX-011 in Metastatic Breast Cancer at American Association for Cancer Research 2007 Annual Meeting
7. AVAX Technologies Presents Results of Phase I-II M-Vax Trial at Annual Meeting of American Association for Cancer Research
8. Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery of GLP-1 and PYY
9. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
10. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
11. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... , Oct. 10, 2017   West Pharmaceutical ... innovative solutions for injectable drug administration, today shared the ... ID Adapter for improving the intradermal administration of polio ... Skin Vaccination Summit in May 2017 by Dr. ... Polio Department, World Health Organization (WHO), and recently published ...
(Date:10/4/2017)... , Oct. 4, 2017 ... single-use, self-contained, illuminating medical devices, today announced regulatory ... Health Surveillance Agency (or Agência Nacional de Vigilância ... first single-use, cordless surgical retractor with integrated LED ... optimal access, illumination and exposure of a tissue ...
(Date:10/2/2017)... Denmark , Oct. 2, 2017 The Rebound ... in the struggle to reverse the tide of prescription drug ... for regulating their medicine intake and stepping down their dosage ... set to launch in December 2017; the first 100,000 people ... Learn more at http://www.rebound-solution.com/ ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... Lori R. Somekh, ... member of ElderCounsel, a national organization of elder law and special needs planning attorneys. ... and rules. It also provides a forum to network with elder law attorneys nationwide,” ...
(Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...
(Date:10/13/2017)... York, NY (PRWEB) , ... October 13, 2017 , ... ... influential people in business to advocate for action towards gender equality at their inaugural ... views from around the globe, and reached a social audience of over 3 million. ...
(Date:10/13/2017)... Abilene, Texas (PRWEB) , ... October 13, 2017 , ... ... publication this week that explains one of the most popular and least understood books ... seems like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... DevOps and Agile Software Development, has been awarded a contract by the Center ... Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in ...
Breaking Medicine News(10 mins):